

REMARKS

Status of Claims

Claims 1-24 have been cancelled. Applicants submit new claims 25 and 26. Claim 25 finds basis throughout the Specification, more particularly on page 62, lines 29-34 and in Figures 6A and Figure 15. Claim 26 finds basis throughout the Specification, more particularly in Figure 15. As such, Applicants submit, no new matter has been added.

Amendments to Sequence listing

Applicants have amended the Sequence listing to correct differences between the sequences listed in Table 6 (Specification page 33) and the Sequence Listing as originally filed. Specifically, Applicants became aware that SEQ ID NO's 87-92 found in Table 6 (page 33 of the Specification) did not match the sequences identified in the Sequence Listing as 87-92. The accompanying Sequence Listing is consistent with Table 6 of the Specification (page 33). Prior SEQ ID NO's 87-92 have been renumbered to SEQ ID NO's 117-122, respectively. Applicants submit no new matter has been added as Applicants are merely correcting inconsistencies between the Specification and the Sequence Listing.

Applicants have also added SEQ ID NO:115 and SEQ ID NO:116 to the Sequence Listing. SEQ ID NO:115 and SEQ ID NO:116 represent sequences in Figure 15 of the present application as filed. Figure 15 as filed referred to SEQ ID NO:109-AME 3-2 Complete Heavy Chain and SEQ ID NO: 110 –AME 3-2 Complete Light Chain, however, SEQ ID NO's 109 and 110 in the Sequence Listing as filed did not match. Applicants have renumbered the SEQ ID NO's of Figure 15 so as to have the next appropriate SEQ ID NO's in the Sequence Listing. Thus, SEQ ID NO: 109 as found in the original Figure 15 of the Specification is now SEQ ID NO: 115 and SEQ ID NO: 110 as found in original Figure 15 is now SEQ ID NO: 116. As the sequences that are now SEQ ID NO:115 and SEQ ID NO:116 were present in originally filed Figure 15 and Applicants are merely correcting an inconsistency between the Sequence Listing and the Specification, Applicants submit that no new matter has been added.

Amendments to the Specification

Applicants submit a replacement paragraph which takes into account the changes made to the SEQ ID NO's of Figure 15 as described. Specifically, the replacement

Serial No. 10/541,260
Docket No. X-16758M

paragraph, amends the Specification (page 11, lines 1-6) to refer to the light chain of AME 3-2 as SEQ ID NO: 116 and the heavy chain of AME 3-2 as SEQ ID NO: 115.

Applicants have amended the Specification to correct SEQ ID NO's so as to match the numbering in the accompanying Sequence listing.

Amendments to the Figures

As indicated above, Figure 15 in the Specification as filed, contained SEQ ID NO: 109 and SEQ ID NO:110, which referred to the AME 3-2 Complete Heavy Chain and the AME 3-2 Complete Light Chain, respectively. However, in the Sequence listing as filed on June 21, 2005, contained sequences identified as SEQ ID NO: 109 and SEQ ID NO:110 that differed from the sequences of Figure 15 of the Specification. Applicants have renumbered the SEQ ID NO's of Figure 15 so as to have the next appropriate SEQ ID NO's in the sequence listing and have added these sequences to the sequence listing. As Applicants are merely correcting an inconsistency between the Sequence Listing and the Specification, Applicants submit that no new matter has been added.

Restriction under 35 U.S.C. 121

The Examiner has required found that the application contains the following groups which are not so linked as to form a single inventive concept under PCT Rule 13.1.

Group I. Claims 2-4 drawn to a composition comprising the polypeptides of SEQ ID NOs: 15, 25 and 33 and 37, 45 and 53 or SEQ ID NOs: 15, 25 and 33 and 39, 45 and 53.

Group II. Claims 5 and 6, drawn to a composition comprising the polypeptides of SEQ ID NOs: 13, 27 and 33 and 37, 55 and 53.

Group III. Claims 9-14, drawn to a composition comprising a TNF- α binding, or a nucleic acid sequence encoding a TNF- α binding molecule.

Group IV. Claims 15-21, drawn to a method of treating a TNF- α mediated disease.

Group V. Claims 22-24, drawn to a composition comprising the polypeptides of SEQ ID NOs: 93, 95, 97, 87, 89 and 91.

Applicants hereby elect Group V. In addition, Applicants submit that newly added Claims 25 and 26 are within Group V.

Serial No. 10/541,260
Docket No. X-16758M

CONCLUSION

Should the Examiner wish to discuss the foregoing in an effort to advance this application towards allowance, the Examiner is urged to telephone the undersigned at the indicated number.

Respectfully submitted,

/Alejandro Martinez/
Alejandro Martinez
Agent for Applicants
Registration No. 58,163
Phone: 317-277-4260

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

9 November 2007